Related Experiment Video

Updated: Oct 14, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

334

Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia

Daniel A Pollyea1, John Barrett2, Courtney D DiNardo3

  • 1Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|November 10, 2021
PubMed

Insights

Project 2025 aims to advance acute myeloid leukemia (AML) drug development by addressing clinical trial design and novel endpoints. Experts convened to outline strategies for continued growth in AML therapeutics.

Area of Science:

  • Oncology
  • Hematology
  • Drug Development

Background:

  • The Food and Drug Administration Oncology Center of Excellence launched Project 2025.
  • Recent successes in acute myeloid leukemia (AML) drug development necessitate strategic planning.

Purpose of the Study:

  • To establish 5-year goals for oncology drug development, focusing on AML.
  • To identify challenges and opportunities in AML clinical trial design and novel endpoints.

Main Methods:

  • Convened a panel of regulators and academic experts in October 2020.
  • Facilitated discussions on optimizing AML drug development strategies.

Main Results:

  • Identified key considerations for advancing AML drug development.
  • Outlined opportunities to maximize recent successes in the field.

Conclusions:

  • Strategic planning is crucial for continued growth in AML therapeutics.
  • Addressing clinical trial design and endpoints will enhance drug development success.

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K